Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
Carregando...
Citações na Scopus
254
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
KOSIBOROD, Mikhail N.
JHUND, Pardeep S.
DOCHERTY, Kieran F.
DIEZ, Mirta
PETRIE, Mark C.
VERMA, Subodh
MERKELY, Bela
KITAKAZE, Masafumi
DEMETS, David L.
Citação
CIRCULATION, v.141, n.2, p.90-99, 2020
Resumo
Background: Goals of management in patients with heart failure and reduced ejection fraction include reducing death and hospitalizations, and improving health status (symptoms, physical function, and quality of life). In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), sodium-glucose cotransporter-2 inhibitor, dapagliflozin, reduced death and hospitalizations, and improved symptoms in patients with heart failure and reduced ejection fraction. In this analysis, we examine the effects of dapagliflozin on a broad range of health status outcomes, using the Kansas City Cardiomyopathy Questionnaire (KCCQ). Methods: KCCQ was evaluated at randomization, 4 and 8 months. Patients were divided by baseline KCCQ total symptom score (TSS); Cox proportional hazards models examined the effects of dapagliflozin on clinical events across these subgroups. We also evaluated the effects of dapagliflozin on KCCQ-TSS, clinical summary score, and overall summary score. Responder analyses were performed to compare proportions of dapagliflozin versus placebo-treated patients with clinically meaningful changes in KCCQ at 8 months. Results: A total of 4443 patients had available KCCQ at baseline (median KCCQ-TSS, 77.1 [interquartile range, 58.3-91.7]). The effects of dapagliflozin vs placebo on reducing cardiovascular death or worsening heart failure were consistent across the range of KCCQ-TSS (lowest to highest tertile: hazard ratio, 0.70 [95% CI, 0.57-0.86]; hazard ratio, 0.77 [95% CI, 0.61-0.98]; hazard ratio, 0.62 [95% CI, 0.46-0.83]; P for heterogeneity=0.52). Patients treated with dapagliflozin had greater improvement in mean KCCQ-TSS, clinical summary score, and overall summary score at 8 months (2.8, 2.5 and 2.3 points higher versus placebo; P<0.0001 for all). Fewer patients treated with dapagliflozin had a deterioration in KCCQ-TSS (odds ratio, 0.84 [95% CI, 0.78-0.90]; P<0.0001); and more patients had at least small, moderate, and large improvements (odds ratio, 1.15 [95% CI, 1.08-1.23]; odds ratio, 1.15 [95% CI, 1.08-1.22]; odds ratio, 1.14 [95% CI, 1.07-1.22]; number needed to treat=14, 15, and 18, respectively; P<0.0001 for all; results consistent for KCCQ clinical summary score and overall summary score). Conclusions: Dapagliflozin reduced cardiovascular death and worsening heart failure across the range of baseline KCCQ, and improved symptoms, physical function, and quality of life in patients with heart failure and reduced ejection fraction. Furthermore, dapagliflozin increased the proportion of patients experiencing at least small, moderate, and large improvements in health status; these effects were clinically important.
Palavras-chave
health status, heart failure, outcome, sodium-glucose transporter 2 inhibitors
Referências
- AstraZeneca, ASTRAZENECA CLIN TRI
- Bender R, 2001, CONTROL CLIN TRIALS, V22, P102, DOI 10.1016/S0197-2456(00)00134-3
- Bui AL, 2011, NAT REV CARDIOL, V8, P30, DOI 10.1038/nrcardio.2010.165
- CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112
- Dewan P, 2019, EUR J HEART FAIL, V21, P577, DOI 10.1002/ejhf.1347
- Ekman I, 2011, EUR HEART J, V32, P2395, DOI 10.1093/eurheartj/ehr343
- Flynn KE, 2009, JAMA-J AM MED ASSOC, V301, P1451, DOI 10.1001/jama.2009.457
- Green CP, 2000, J AM COLL CARDIOL, V35, P1245, DOI 10.1016/S0735-1097(00)00531-3
- Lewis EF, 2001, J HEART LUNG TRANSPL, V20, P1016, DOI 10.1016/S1053-2498(01)00298-4
- Lewis EF, 2017, CIRC-HEART FAIL, V10, DOI 10.1161/CIRCHEARTFAILURE.116.003430
- McMurray JJV, 2019, NEW ENGL J MED, V381, P1995, DOI 10.1056/NEJMoa1911303
- McMurray JJV, 2019, EUR J HEART FAIL, DOI 10.1002/ejhf.1548
- McMurray JJV, 2019, EUR J HEART FAIL, V21, P665, DOI 10.1002/ejhf.1432
- Nassif ME, 2019, CIRCULATION, V140, P1463, DOI 10.1161/CIRCULATIONAHA.119.042929
- Reddy P, 2000, PHARMACOTHERAPY, V20, P679, DOI 10.1592/phco.20.7.679.35178
- Spertus J, 2005, AM HEART J, V150, P707, DOI 10.1016/j.ahj.2004.12.010
- TSEVAT J, 1994, J GEN INTERN MED, V9, P576, DOI 10.1007/BF02599287
- U.S. Food and Drug Administration, TREATM HEART FAIL EN
- Veazie PJ, 2012, J AM COLL CARDIOL, V60, P1940, DOI 10.1016/j.jacc.2012.06.054